Salvage surgery after chemoradiotherapy in the management of esophageal cancer

LAUR Repository

Show simple item record

dc.contributor Chemaly, Rodrigue
dc.contributor.author Markar, Sheraz
dc.contributor.author Gronnier, Caroline
dc.contributor.author Duhamel, Alain
dc.contributor.author Pasquer, Arnaud
dc.contributor.author Théreaux, Jérémie
dc.contributor.author Du Rieu, Mael Chalret
dc.contributor.author Lefevre, Jérémie H.
dc.contributor.author Turner, Kathleen
dc.contributor.author Luc, Guillaume
dc.contributor.author Mariette, Christophe
dc.date.accessioned 2022-11-03T14:22:20Z
dc.date.available 2022-11-03T14:22:20Z
dc.date.copyright 2015 en_US
dc.date.issued 2022-11-03
dc.identifier.issn 0732-183X en_US
dc.identifier.uri http://hdl.handle.net/10725/14212
dc.description.abstract Purpose: The aim of this large multicenter study was to assess the impact of salvage esophagectomy after definitive chemoradiotherapy (SALV) on clinical outcome. Patients and methods: Data from consecutive adult patients undergoing resection for esophageal cancer in 30 European centers from 2000 to 2010 were collected. First, groups undergoing SALV (n = 308) and neoadjuvant chemoradiotherapy followed by planned esophagectomy (NCRS; n = 540) were compared. Second, patients who benefited from SALV for persistent (n = 234) versus recurrent disease (n = 74) were compared. Propensity score matching and multivariable analyses were used to compensate for differences in some baseline characteristics. Results: SALV versus NCRS groups: In-hospital mortality was similar in both groups (8.4% v 9.3%). The only significant differences in complications were seen for anastomotic leak (17.2% v 10.7%; P = .007) and surgical site infection, which were both more frequent in the SALV group. At 3 years, groups had similar overall (43.3% v 40.1%; P = .542) and disease-free survival (39.2% v 32.8%; P = .232) after matching, along with a similar recurrence pattern. Persistent versus recurrent disease groups: There were no significant differences between groups in incidence of in-hospital mortality or major complications. At 3 years, overall (40.9% v 56.2%; P = .046) and disease-free survival (36.6% v 51.6%; P = .095) were lower in the persistent disease group. Conclusion: The results of this large multicenter study from the modern era suggest that SALV can offer acceptable short- and long-term outcomes in selected patients at experienced centers. Persistent cancer after definitive chemoradiotherapy seems to be more biologically aggressive, with poorer survival compared with recurrent cancer. en_US
dc.language.iso en en_US
dc.title Salvage surgery after chemoradiotherapy in the management of esophageal cancer en_US
dc.type Article en_US
dc.description.version Published en_US
dc.title.subtitle is it a viable therapeutic option? en_US
dc.author.school SOM en_US
dc.author.idnumber 201805037 en_US
dc.author.department N/A en_US
dc.relation.journal Journal of Clinical Oncology (JCO) en_US
dc.journal.volume 33 en_US
dc.journal.issue 33 en_US
dc.article.pages 3866-3873 en_US
dc.identifier.doi https://doi.org/10.1200/JCO.2014.59.9092 en_US
dc.identifier.ctation Markar, S., Gronnier, C., Duhamel, A., Pasquer, A., Théreaux, J., du Rieu, M. C., ... & Mariette, C. (2015). Salvage Surgery After Chemoradiotherapy in the Management of Esophageal Cancer: Is It a Viable Therapeutic Option?. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 33(33), 3866-3873. en_US
dc.author.email rodrigue.chemaly@lau.edu.lb en_US
dc.identifier.tou http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php en_US
dc.identifier.url https://pubmed.ncbi.nlm.nih.gov/26195702/ en_US
dc.orcid.id https://orcid.org/0000-0002-3670-6027 en_US
dc.author.affiliation Lebanese American University en_US

Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search LAUR

Advanced Search


My Account